- Home
- DXR
as 03-28-2025 4:00pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 40.3M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 10.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | 86.16 |
| 52 Week Low/High: | $6.55 - $10.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $119,714 | Revenue Growth: | -26.75% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Daxor Corporation (DXR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Feldschuh Michael Richard | DXR | Chief Executive Officer | Mar 19 '25 | Buy | $8.15 | 647 | $5,273.05 | 209,631 | |
| Michel Robert J | DXR | Chief Financial Officer | Mar 10 '25 | Buy | $8.00 | 1,000 | $8,000.00 | 17,050 |
Latest Daxor Corporation News
DXR Breaking Stock News: Dive into DXR Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
GlobeNewswire
a month ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
GlobeNewswire
a month ago
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
GlobeNewswire
a month ago
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
GlobeNewswire
a month ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
GlobeNewswire
a month ago
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
GlobeNewswire
a month ago
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
GlobeNewswire
a month ago
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
Compare DXR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.